Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2013-01-04 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA : Bilan annuel du contrat de liquidité d'Innate Pharma à la Société de Bourse Gilbert Dupont
Regulatory Filings Classification · 99% confidence The document is titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITÉ D'INNATE PHARMA AVEC LA SOCIÉTÉ DE BOURSE GILBERT DUPONT" (Annual Balance of the Liquidity Contract) and reports the status of shares and cash held under a liquidity agreement as of December 31, 2012. This type of report details transactions or holdings related to the company's own shares, specifically in the context of a market-making or liquidity provision agreement. This aligns closely with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities, including those managed via liquidity contracts. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it is highly specific to share transactions.
2013-01-04 French
Innate Pharma annonce son calendrier financier pour 2013 ainsi que ses prochains rendez-vous investisseurs
Report Publication Announcement Classification · 99% confidence The document is titled "INNATE PHARMA ANNONCE SON CALENDRIER FINANCIER POUR 2013 AINSI QUE SES PROCHAINS RENDEZ-VOUS INVESTISSEURS" (Innate Pharma Announces its Financial Calendar for 2013 as well as its Upcoming Investor Meetings). It explicitly lists future dates for financial report publications (Q4 2012 revenue, Annual results 2012, Q1 2013 revenue, etc.) and investor events. This content is a forward-looking announcement about the schedule of future corporate disclosures and investor relations activities, rather than the reports themselves (like 10-K or ER). Since it announces the schedule for future reports and investor meetings, it fits best under the category of announcing the publication of reports or general investor communication scheduling. Given the options, it is an announcement regarding the timing/schedule of future corporate reports and investor engagement, making 'Report Publication Announcement' (RPA) the most appropriate fit, as it details when reports will be released. It is not a full report, a transcript, or a specific regulatory filing like DIRS or DIV.
2012-12-19 French
Innate Pharma announces its financial calendar for 2013 and its participation to upcoming investor conferences
Report Publication Announcement Classification · 99% confidence The document is titled "INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2013 AS WELL AS ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCES". It outlines future dates for the publication of revenues, financial statements, and the Annual Shareholders Meeting. It also lists upcoming investor conferences the management will attend. This document is not the financial report itself (like 10-K or IR), nor is it a transcript (CT) or a formal dividend notice (DIV). It is an announcement about future corporate events and reporting schedules. This fits best under the category of announcing the publication of reports or general corporate updates related to investor relations, which aligns closely with Report Publication Announcement (RPA) or potentially Regulatory Filings (RNS) if RPA is too specific. Since it explicitly announces the *publication* schedule for financial reports and investor participation, RPA is the most precise fit, as it signals forthcoming information releases.
2012-12-19 English
Innate Pharma : Phase I clinical trial of IPH2102/BMS-986015 in combination with ipilimumab announced
Investor Presentation Classification · 92% confidence The document is a press release dated December 19, 2012, announcing the publication of details for a Phase I clinical trial (IPH2102/BMS-986015) on ClinicalTrials.gov. It discusses ongoing clinical development, partnerships (with Bristol-Myers Squibb), and provides general company information. This type of announcement, detailing clinical trial progress and partnership updates, is characteristic of an Investor Presentation (IP) or a general press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it details strategy, pipeline progress, and scientific updates aimed at investors, Investor Presentation (IP) is the most fitting category, although it is structured as a press release. Given the options, it is a detailed update on the company's core business (drug development) aimed at the investment community, which aligns closely with the purpose of an Investor Presentation, rather than a simple Regulatory Filing (RNS) or Earnings Release (ER). It is not a formal financial report (10-K, IR) or a management discussion (MDA).
2012-12-19 English
Innate Pharma : Annonce d'un essai clinique de Phase I avec IPH2102/BMS-986015 en combinaison avec ipilimumab
Regulatory Filings Classification · 97% confidence The document is a press release dated December 19, 2012, from Innate Pharma announcing that a Phase I clinical trial for their drug IPH2102/BMS-986015 in combination with ipilimumab has been published on ClinicalTrials.gov. The text details the objectives, patient population, and background of the clinical trial, and also mentions other ongoing trials and licensing agreements. This type of announcement, detailing clinical trial progress and publication, is characteristic of an Investor Presentation (IP) or a general regulatory/investor update. Since it is a formal announcement detailing scientific and clinical progress intended for investors and stakeholders, Investor Presentation (IP) is the most fitting category, as it often includes such detailed scientific updates, even if it's not strictly a slide deck. It is not a full Annual Report (10-K), an Earnings Release (ER) focusing only on financial highlights, or a simple Report Publication Announcement (RPA) as it contains substantial new information about the trial itself, not just a notice that a report is available. Given the focus on clinical development and partnership details, IP is the best fit among the provided options.
2012-12-19 French
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH) : Premier patient traité dans l'essai EffiKIR
Regulatory Filings Classification · 92% confidence The document is a press release dated December 17, 2012, announcing that the first patient has been treated in the EffiKIR Phase II trial for the drug IPH2102/BMS-986015. It details the trial design (Phase II, randomized, placebo-controlled), the indication (AML), the mechanism of action of the drug, and mentions licensing agreements with Bristol-Myers Squibb. This content is characteristic of an announcement regarding clinical trial progress or a significant operational update, rather than a formal regulatory filing like a 10-K, a quarterly report (IR), or a formal earnings release (ER). Since it is a specific announcement about a clinical development milestone, it fits best under the general category of Investor Information or a specific regulatory filing if one existed. Given the options, this is a specific corporate update about drug development. It is not a standard Earnings Release (ER), nor a comprehensive Interim Report (IR). It is a press release detailing operational/clinical progress. In the context of the provided definitions, this type of announcement, which is not a financial report, management change, or shareholder vote result, often falls under general Regulatory Filings (RNS) or, if it were more focused on strategy/financials for investors, an Investor Presentation (IP). However, since it is a direct announcement of a clinical event, and not a presentation deck, RNS is the most appropriate fallback for a specific, non-listed corporate event announcement, or potentially a Capital/Financing Update (CAP) if the focus was on funding, which it is not. Given the nature of clinical trial updates being common regulatory disclosures, RNS (Regulatory Filings) is the most suitable general category for this type of press release when a more specific clinical trial update code is unavailable. It is not short enough to be an RPA based on the 'Menu vs Meal' rule, as it contains substantial detail about the science and business context.
2012-12-17 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.